The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study

References

• Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–24.
   PubMed Web of Science ®Google Scholar
• Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529–34.
   PubMed Web of Science ®Google Scholar
• Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol. 2012;22: 337–44.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Dierkhising RA, Crowson CS, et al. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol. 2013;52:32–40.
   PubMed Web of Science ®Google Scholar
• Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48:839–46.
   PubMed Web of Science ®Google Scholar
• Campanati A, Ganzetti G, Di Sario A, et al. Insulin resistance, serum insulin and HOMA-R. J Gastroenterol. 2013;48:673.
   PubMed Web of Science ®Google Scholar
• Campanati A, Goteri G, Simonetti O, et al. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept . Br J Dermatol. 2007;157:1155–60.
   PubMed Web of Science ®Google Scholar
• Orciani M, Campanati A, Salvolini E, et al. The mesenchymal stem cell profile in psoriasis. Br J Dermatol. 2011;165: 585–92.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Rostamil-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20:81–7.
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93: S64–S73.
   PubMed Web of Science ®Google Scholar
• Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157:649–55.
   PubMed Web of Science ®Google Scholar
• Kershaw EE Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.
   PubMed Web of Science ®Google Scholar
• Campanati A, Moroncini G, Ganzetti G, et al. Adalimumab modulates angiogenesis in psoriatic skin. Eur J Inflam. 2013;11:489–98.
   Web of Science ®Google Scholar
• Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11: 11–18.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Mouritsen E, Holm J, et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord. 2003;27:941–9.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341–4.
   PubMed Web of Science ®Google Scholar
• Prignano F, Ricceri F, Pescitelli L, et al. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. Curr Med Res Opin. 2009;25:2311–6.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31:433–42.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149:84–91.
   PubMed Web of Science ®Google Scholar
• Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014;63:1115–23.
   PubMed Web of Science ®Google Scholar
• Després JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38:52–63.
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Campanati A, Offidani A. Alopecia areata: a possible extraintestinal manifestation of Crohn's disease. J Crohns Colitis. 2012;6:962–3.
   PubMed Web of Science ®Google Scholar
• Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67:768–73.
   PubMed Web of Science ®Google Scholar
• Ahdout J, Kotlerman J, Elashoff D, et al. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin Exp Dermatol. 2012;37:477–83.
   PubMed Web of Science ®Google Scholar
• Naldi L, Conti A, Cazzaniga S, et al. The Psoriasis Emilia Romagna Study Group. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014;170:634–42.
   PubMed Web of Science ®Google Scholar
• Kim GE, Seidler E, Kimball AB. The relative impact of psoriasis and obesity on socioeconomic and medical outcomes in psoriasis patients. J Eur Acad Dermatol Venereol. 2014;28:216–21.
   PubMed Web of Science ®Google Scholar
• Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol. 2008;121:326–30.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006;110:267–78.
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.
   PubMed Web of Science ®Google Scholar
• Gable DR, Hurel SJ, Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis. 2006;188:231–44.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity linked insulin resistance. Science. 1993;259:87–91.
   PubMed Web of Science ®Google Scholar
• Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111–19.
   PubMed Web of Science ®Google Scholar
• Li YP, Lecker SH, Chen Y, et al. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220K. FASEB J. 2003;17:1048–57.
   PubMed Web of Science ®Google Scholar
• Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol. 2013;54:259–63.
   PubMed Web of Science ®Google Scholar
• Florin V, Cottencin AC, Delaporte E, Staumont-Sallé D. Body weight increment in patients treated with infliximab for plaque psoriasis. J Eur Acad Dermatol Venereol. 2013;27:e186–90.
   PubMed Web of Science ®Google Scholar
• Campanati A, Giuliodori K, Ganzetti G, et al. A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol. 2010;11:46–8.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Tasin L, Pellicano R, et al. Impact of body mass index on retention rates of anti-TNF-alpha drugs in daily practice for psoriasis. J Dermatolog Treat. 2012;23:404–9.
   PubMed Web of Science ®Google Scholar
• Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443–6.
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25:1007–11.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Balestri R, Baldi E, et al. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther. 2010;23:S14–S19.
   PubMed Web of Science ®Google Scholar
• De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13:1673–82.
   PubMed Web of Science ®Google Scholar
• Amin F, Fatima SS, Islam N, Gilani AH. Prevalence of obesity and overweight, its clinical markers and associated factors in a high risk South-Asian population. BMC Obes. 2015;2:16–18.
   PubMedGoogle Scholar
• Wilkinson ML, Brown AL, Poston WS, et al. Physician weight recommendations for overweight and obese firefighters, United States, 2011–2012. Prev Chronic Dis. 2014;11:E116.
   PubMed Web of Science ®Google Scholar